Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsPsychopharmacology — clozapine

Psych MEQs / SAQs · Psychopharmacology — clozapine

Initiating clozapine in treatment-resistant schizophrenia (MEQ)

FRANZCP-style MEQ on clozapine entry criteria, initiation, monitoring, smoking interaction, and CIGH prevention.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 26-year-old man with schizophrenia has failed two adequate adherent antipsychotic trials (olanzapine then aripiprazole). Persistent positive symptoms, BMI 29, smokes 20 cigarettes/day, no cardiac history. He and his family are anxious about 'the dangerous blood drug'. (i) Define TRRIP-style treatment resistance and justify offering clozapine. (ii) List pre-start investigations and service prerequisites. (iii) Outline a slow titration plan and first-month safety monitoring including myocarditis vigilance. (iv) Explain smoking/CYP1A2 counselling and a plasma-level approach if non-response. (v) State how you would prevent and recognise life-threatening constipation. (20 marks)

Model answer

Reveal model answer

(i) TRRIP and offer. Treatment-resistant schizophrenia: confirmed schizophrenia-spectrum diagnosis; inadequate response to at least two different antipsychotics at adequate dose and duration with adherence confirmed; exclude pseudo-resistance (substances, under-dosing, non-adherence, organic mimics). Kane established clozapine superiority in TRS; Siskind meta-analyses support meaningful response rates and earlier use. Offer clozapine with full monitoring — not endless non-clozapine polypharmacy. Mention InterSePT if suicide risk is prominent.[1][2][3][7]

(ii) Pre-start. FBC/ANC, metabolic panel, weight/BMI/waist, ECG, CRP ± troponin per local myocarditis protocol, U&E/LFT, pregnancy test if relevant, smoking history, medication review (avoid carbamazepine; caution fluvoxamine). Confirm registry enrolment and that the team can obtain protocol bloods and act on red results. Shared decision with honest risk–benefit counselling.[4]

(iii) Titration and first month. Start 12.5 mg; slow stepwise rise over days–weeks toward an individualised adult target often in the 200–450 mg/day range. First-month cardiac vigilance: fever, unexplained tachycardia, chest pain → stop and investigate myocarditis (ECG, CRP, troponin, cardiology). Haematology per local schedule (commonly weekly early). Metabolic and bowel monitoring from day one.[4]

(iv) Smoking and levels. Cigarette smoking induces CYP1A2 and lowers clozapine levels; smokers often need higher doses; cessation raises levels and toxicity risk — plan level checks and possible dose reduction if he stops smoking. If non-response at adequate dose, check trough level (classic teaching ~0.35 mg/L / 350 ng/mL as a response threshold scaffold) and individualise.[5]

(v) Constipation/CIGH. Proactive laxative protocol and bowel chart from initiation. Teach red flags: severe constipation, vomiting, distension, no flatus. Escalation: stop clozapine, surgical review — life-threatening hypomotility is documented in large series.[6]

Common errors

  • Declaring resistance after non-adherent micro-doses rather than TRRIP-adequate trials.[1]
  • Starting without monitoring capacity or registry pathway.[4]
  • Ignoring first-month myocarditis symptoms as "viral".[4]
  • Forgetting smoking cessation as a toxicity risk on the ward.[5]
  • Treating constipation as trivial PRN advice only.[6]

References

  1. [1]Howes OD, McCutcheon R, Agid O, et al. Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology Am J Psychiatry, 2017.PMID 27919182
  2. [2]Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 1988.PMID 3046553
  3. [3]Siskind D, Siskind V, Kisely S Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis Can J Psychiatry, 2017.PMID 28655284
  4. [4]Ronaldson KJ, Taylor AJ, Fitzgerald PB, et al. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatry, 2010.PMID 20361910
  5. [5]Rostami-Hodjegan A, Amin AM, Spencer EP, et al. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol, 2004.PMID 14709950
  6. [6]Palmer SE, McLean RM, Ellis PM, et al. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry, 2008.PMID 18452342
  7. [7]Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Arch Gen Psychiatry, 2003.PMID 12511175